|Room 4331, 3th building, high-tech industrial park, yizhi road, qingshan district, wuhan, China||Body@bodybiological.com|
|Place of Origin:||Hubei, China|
|Minimum Order Quantity:||10gram|
|Packaging Details:||Foil bag|
|Delivery Time:||within 24 hours after the payment|
|Payment Terms:||T/T, Western Union, MoneyGram|
|Appearance:||White Powder||Shipping Method:||FEDEX, TNT, DHL, UPS, HK EMS|
|Payment Terms:||Money Gram, Western Union, Bank Transfer||Export Market:||USA, UK, Brazil, Thailand, Canada|
anti estrogen supplements,
bodybuilding estrogen blocker
Treatment Receptor Fulvestrant CAS 129453-61-8 Anti Estrogen Steroids
|Product Name||Fulvestrant Faslodex|
Fulvestrant, sold under the trade name Faslodex among others, is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.
Fulvestrant was approved for medical use in the United States in 2002.
Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women; it is given by injection. A 2017 Cochrane review found it is as safe and effective as first line or second line endocrine therapy.
It is also used to treat HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after first-line endocrine therapy.
It should not be used in women with kidney failure or who are pregnant.
Due to the medication having a similar chemical structure to estrogen, it can interact with immunoassays for blood estradiol concentrations and show falsely elevated results. This can improperly lead to discontinuing the treatment.
Fulvestrant was studied in endometrial cancer but results were not promising and as of 2016 development for this use was abandoned.
Because fulvestrant is a steroid and cannot be given orally, efforts have been made to develop SERD drugs that can be taken by mouth, including brilanestrant and elacestrant. The clinical success of fulvestrant also led to efforts to discover and develop a parallel drug class of selective androgen receptor degraders (SARDs).
Have a low level of platelets in your blood or bleed easily. Especially tell your healthcare provider if you take a blood thinner medicine (anticoagulants)
Have liver problems
Are pregnant or plan to become pregnant, as FASLODEX can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with FASLODEX and for one year after the last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant while on FASLODEX
Are breast-feeding or plan to breast-feed. It is not known if FASLODEX passes into breast milk. Do not breast-feed during treatment with FASLODEX and for one year after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time.
Other related products:
|Testosterone Acetate||Trenbolone Acetate||MGF|
|Testosterone Cypionate||Trenbolone Enanthate||PEG MGF|
|Testosterone Decanoate||Boldenone Acetate||CJC-1295|
|Testosterone Enanthate||Boldenone undecylenate||CJC-1295 DAC|
|Testosterone Isocaproate||Boldenone Cypionate||PT-141|
|Testosterone Propionate||Nandrolone Decanoate||Melanotan-2|
|Testosterone Undecanoate||Nandrolone phenylpropionate||GHRP-2|
|Testosterone Sustanon 250||Nandrolone cypionate||Ipamorelin|
|Clostebol Acetate||Nandrolone propionate||Hexarelin|
|Methenolone Enanthate||Drostanolone Propionate||Oxytocin|
|Methenolone Acetate||Drostanolone Enanthate||TB500|
Contact Person: Penny